A5088502545- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Treatments and Mutations
- Appendicitis Diagnosis and Management
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Science, Research, and Medicine
- Mycobacterium research and diagnosis
- Ovarian cancer diagnosis and treatment
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Neuroendocrine Tumor Research Advances
- Molecular Biology Techniques and Applications
- RNA and protein synthesis mechanisms
- Colorectal and Anal Carcinomas
- Estrogen and related hormone effects
- Ubiquitin and proteasome pathways
- Genetics and Neurodevelopmental Disorders
- Vitamin D Research Studies
- Advanced X-ray and CT Imaging
- Epigenetics and DNA Methylation
Stanford University
2024-2025
The Netherlands Cancer Institute
2018-2024
Oncode Institute
2020-2023
Stanford Medicine
2023
University Medical Center Utrecht
2022
Dutch Cancer Society
2019-2020
Wageningen University & Research
2019
Abstract Background Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard treatment for isolated resectable colorectal peritoneal metastases (PM) in Netherlands. This study investigates whether addition of perioperative systemic therapy to CRS-HIPEC improves oncological outcomes. Methods open-label, parallel-group, phase II-III, randomised, superiority performed nine Dutch tertiary referral centres. Eligible patients are adults who have a good performance status,...
<h3>Importance</h3> To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM). <h3>Objective</h3> assess the feasibility safety of in patients with CPM response neoadjuvant treatment. <h3>Design, Setting, Participants</h3> An open-label, parallel-group phase 2 trial all 9 Dutch tertiary centers surgical treatment...
Abstract Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction validate method in two independent cohorts patients colorectal or lung cancer. DELFI-TF scores strongly correlate circulating levels (ctDNA) (r = 0.90, p...
Abstract Purpose: Circulating tumor DNA (ctDNA) has the potential to guide therapy selection and monitor treatment response in patients with metastatic cancer. However, germline clonal hematopoiesis–associated alterations can confound identification of tumor-specific mutations cell-free (cfDNA), often requiring additional sequencing tissue. The current study assessed whether ctDNA-based monitoring could be performed a tissue–independent manner by combining ultra-deep targeted analyses cfDNA...
Abstract Tumor‐derived cell‐free DNA (cfDNA) is an emerging biomarker for guiding the personalized treatment of patients with metastatic colorectal cancer (CRC). While CRC liver metastases (CRC‐LM) have relatively high levels plasma cfDNA, little known about peritoneal (CRC‐PM). This study evaluated presence tumor‐derived cfDNA in and fluid (i.e. ascites or washing) 20 isolated CRC‐PM 100 CRC‐LM. Among tumor tissue KRAS/BRAF mutation carriers, was detected by droplet digital polymerase chain...
Recurrence rates after resection of colorectal cancer liver metastases (CRLM) are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is a promising prognostic biomarker. Focusing on patients resected CRLM, this study aimed to evaluate the association between detection postoperative ctDNA, pathologic response recurrence-free survival (RFS).Twenty-three were selected from an ongoing phase-3 trial who underwent RAS-mutant CRLM induction systemic treatment....
Introduction Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients isolated unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little known about its feasibility, safety, tolerability, efficacy, costs and pharmacokinetics this setting. This study aims to explore these parameters PM who receive repetitive ePIPAC-OX monotherapy. Methods analysis...
PURPOSE Somatic KRAS mutations occur in approximately half of the patients with metastatic colorectal cancer (mCRC). Biologic tumor characteristics differ on basis mutation variant. are known to influence patient prognosis and used as predictive biomarker for treatment decisions. This study examined clinical features mCRC a somatic G12, G13, Q61, K117, or A146. METHODS A total 419 initially unresectable liver-limited metastases, who participated multicenter prospective trial, were evaluated...
Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D3) before, directly after 6 months chemotherapy in breast cancer patients (n = 95), a comparison group women 52) not diagnosed with cancer. Changes 25(OH)D3 over time were compared using linear mixed models adjusted for age season blood sampling. Before start chemotherapy, lower (estimated marginal mean 55.8 nmol/L, 95%...
Introduction Despite its increasing use, first-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy oxaliplatin (ePIPAC-OX), hereinafter referred to as bidirectional therapy, has never been prospectively investigated in patients colorectal peritoneal metastases (CPM). As a first step address this evidence gap, the present study aims assess safety, feasibility, antitumour activity, patient-reported outcomes, costs and pharmacokinetics...
e15664 Background: Currently available circulating cell-free DNA (cfDNA) assays require deep-targeted sequencing to detect cancer-specific mutations at low mutant allele frequency (MAF) levels in the blood. Recently, we developed a tumor-agnostic, mutation-independent approach that utilizes low-coverage whole genome called DELFI (DNA evaluation of fragments for early interception) Tumor Fraction (DELFI-TF), model designed predict plasma tumor fractions based on genome-wide...
Abstract BACKGROUND: Cell-free circulating tumor DNA (ctDNA) assays have been adopted to monitor therapeutic response in both early- and late-stage cancer. However, tests currently available require deep-targeted sequencing detect cancer-specific mutations at low mutant allele frequency (MAF) levels the circulation. Recently, we developed a tumor-agnostic approach called DELFI Tumor Fraction (DELFI-TF), Bayesian probabilistic model designed predict plasma fractions based on genome-wide...
For patients with colorectal cancer liver metastases (CRLM), the genetic mutation status is important in treatment selection and prognostication for survival outcomes. This study aims to investigate relationship between radiomics imaging features (KRAS versus no mutation) a large multicenter dataset of CRLM validate these findings an external dataset. Patients initially unresectable treated systemic therapy randomized controlled CAIRO5 trial (NCT02162563) were included. All...
Abstract Introduction: Circulating tumor DNA (ctDNA) from plasma is a promising biomarker. Patients with metastatic colorectal cancer (CRC) often have high ctDNA levels compared to other types. However, it unclear whether this also the case for patients peritoneal metastases CRC. Aim: To compare propensity of shedding by isolated liver and Methods: Plasma was collected 100 CRC (64% male, mean age 60 [SD=10] years) unresectable metastasis (CRC-LM). ascites were obtained 20 (60% 63 [SD=9.8]...
Circulating tumor DNA (ctDNA) detection has multiple promising applications in oncology, but the road toward implementation clinical practice is unclear. We aimed to support process by exploring potential future pathways of ctDNA testing. To do so, we studied four ctDNA‐testing two cancer types and elicited opinions from 30 experts Netherlands. Our results showed that current available evidence differed per application type. Tumor profiling monitoring treatment response were found most...
<div>AbstractPurpose:<p>Circulating tumor DNA (ctDNA) has the potential to guide therapy selection and monitor treatment response in patients with metastatic cancer. However, germline clonal hematopoiesis–associated alterations can confound identification of tumor-specific mutations cell-free (cfDNA), often requiring additional sequencing tissue. The current study assessed whether ctDNA-based monitoring could be performed a tissue–independent manner by combining ultra-deep...
<div>AbstractPurpose:<p>Circulating tumor DNA (ctDNA) has the potential to guide therapy selection and monitor treatment response in patients with metastatic cancer. However, germline clonal hematopoiesis–associated alterations can confound identification of tumor-specific mutations cell-free (cfDNA), often requiring additional sequencing tissue. The current study assessed whether ctDNA-based monitoring could be performed a tissue–independent manner by combining ultra-deep...
<p>Supplementary Data 1 shows an overview of ctDNA dynamics, treatments, and radiological response measurements per patient.</p>